Prevention of Deep Vein Thrombosis by Panax Notoginseng Saponins Combined with Low-Molecular-Weight Heparin in Surgical Patients

被引：0
|
作者：
Chun-mei Wang
Xiang-feng Guo
Li-min Liu
Ying Huang
Liang Meng
Li-po Song
Ying-feng Wu
Ya-chan Ning
Kathleen H. Reilly
Hai-bo Wang
机构：
[1] Capital Medical University,Department of Vascular Surgery, Xuanwu Hospital
[2] Children’s Hospital Capital Institute of Pediatrics,Department of Orthopaedics, Xuanwu Hospital
[3] Capital Medical University,Peking University Clinical Research Institute
[4] Centers for Disease Control and Prevention,undefined
[5] Peking University First Hospital,undefined
来源：
Chinese Journal of Integrative Medicine | 2022年 / 28卷
关键词：
panax notoginseng saponins; deep vein thrombosis; low-molecular-weight heparin; thromboelastography; risk factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：771 / 778
页数：7
相关论文
共 50 条
  • [21] PREVENTION OF DEEP-VEIN THROMBOSIS BY LOW-MOLECULAR-WEIGHT HEPARIN AND DIHYDROERGOTAMINE IN PATIENTS UNDERGOING TOTAL HIP-REPLACEMENT
    FREICK, H
    HAAS, S
    THROMBOSIS RESEARCH, 1991, 63 (01) : 133 - 143
  • [22] Low molecular weight heparin for deep vein thrombosis in glioma patients
    Schmidt, F
    Faul, C
    Dichgans, J
    Weller, M
    JOURNAL OF NEUROLOGY, 2002, 249 (10) : 1409 - 1412
  • [23] Low molecular weight heparin for deep vein thrombosis in glioma patients
    Friederike Schmidt
    Christoph Faul
    Johannes Dichgans
    Michael Weller
    Journal of Neurology, 2002, 249 : 1409 - 1412
  • [24] Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient setting?
    Lindmarker, P
    HAEMOSTASIS, 1999, 29 : 84 - 88
  • [25] LOW-MOLECULAR-WEIGHT HEPARIN WITHOUT ORAL ANTICOAGULANTS FOR THE TREATMENT OF DEEP VEIN THROMBOSIS
    Alonso Martinez, J. L.
    Abinzano Guillen, M. L.
    Urbieta Echezarreta, M. A.
    Annicherico Sanchez, F. J.
    Fernandez Ladron, V.
    Garcia Sanchotena, J. L.
    ANALES DE MEDICINA INTERNA, 2008, 25 (01) : 4 - 8
  • [26] Deep vein thrombosis (DVT) in childhood: Treatment with low-molecular-weight heparin (LMWH)
    Aversa, L
    Vazquez, A
    Bustelo, P
    THROMBOSIS AND HAEMOSTASIS, 1999, : 200 - 200
  • [27] Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
    Harrison, L
    McGinnis, J
    Crowther, M
    Ginsberg, J
    Hirsh, J
    ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (18) : 2001 - 2003
  • [28] Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep-vein thrombosis in stroke patients
    Hillbom, M
    Erilä, T
    Flosbach, C
    Sotaniemi, K
    Tatlisumak, T
    Sarna, S
    Kaste, M
    STROKE, 1998, 29 (01) : 304 - 304
  • [29] The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients
    Lee, Tim H.
    Alonzo, Brock J.
    Differding, Jerome
    Underwood, Samantha J.
    Hamilton, Greg
    Kremenevskiy, Igor
    McNamara, Steve
    Schreiber, Martin A.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2013, 74 (02): : 476 - 481
  • [30] EFFICACY AND SAFETY OF A LOW-MOLECULAR-WEIGHT HEPARIN ( LMW-HEPARIN SANDOZ ) IN PATIENTS WITH DEEP-VEIN THROMBOSIS
    VOGEL, G
    MACHULIK, M
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 120 - 120
12345